Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
Diabetes, Obesity and Metabolism · 2024-03 · 26 (3) · 891-900
DOI: 10.1111/dom.15382 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 29.11.2023. Verfasst von Giovanni Antonio Silverii und 7 weiteren Autor:innen. Beteiligte Einrichtung: AOU Careggi, Diabetology Unit-Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Thyroid Neoplasms. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Italian Ministry of Health (Ricerca Corrente), IRCCS MultiMedica.
Abstract (Originalsprache)
Aim
To conduct a meta‐analysis of randomized clinical trials (RCTs) to investigate whether there is an association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) treatment and thyroid cancer. Materials and Methods In this meta‐analysis of RCTs, we included studies comparing a GLP‐1RA with any comparator, lasting at least 52 weeks, and reporting the incidence of adverse events independently of the principal endpoint and population. All cases of thyroid cancer were collected.
Results
We retrieved 64 trials, 26 of which reported at least one incident case of thyroid cancer. GLP‐1RA treatment was associated with a significant increase in the risk of overall thyroid cancer (Mantel‐Haenzel odds ratio [MH‐OR] 1.52 [95% confidence interval {CI} 1.01, 2.29]; P = 0.04, I 2 = 0%), with a fragility index of 1, and a 5‐year number needed to harm of 1349. The association remained significant when including only trials lasting at least 104 weeks (MH‐OR 1.76 [95% CI 1.00, 3.12]; P = 0.05). No significant association was found for papillary thyroid cancer (MH‐OR 1.54 [95% CI 0.77, 3.06]; P = 0.22) or medullary thyroid cancer (MH‐OR 1.44 [95% CI 0.23, 9.16]; P = 0.55).
Conclusions
Our meta‐analysis showed that GLP‐1RA treatment could be associated with a moderate increase in relative risk for thyroid cancer in clinical trials, with a small increase in absolute risk. Studies of longer duration are required to assess the clinical implications of this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AOU Careggi, Diabetology Unit-Experimental and Clinical Biomedical Sciences "Mario Serio" Department, University of Florence, Florence, Italy.
- Endocrinology and Metabolic Diseases Unit, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- IRCCS MultiMedica, Milan, Italy.
- Italian Association of Clinical Diabetologists, Rome, Italy.
ORCID-Profile: Giovanni Antonio Silverii, Matteo Monami, Francesco Prattichizzo, Antonio Ceriello, Edoardo Mannucci
Förderung
- the Italian Ministry of Health (Ricerca Corrente)
- IRCCS MultiMedica
Zitieren
APA
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024). Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 26(3), 891-900. https://doi.org/10.1111/dom.15382
Vancouver
Silverii GA, Monami M, Gallo M, Ragni A, Prattichizzo F, Renzelli V, et al. Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2024;26(3):891-900. doi:10.1111/dom.15382
BibTeX
@article{Silverii2024,
author = {Silverii, Giovanni Antonio and Monami, Matteo and Gallo, Marco and Ragni, Alberto and Prattichizzo, Francesco and Renzelli, Valerio and Ceriello, Antonio and Mannucci, Edoardo},
title = {Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {3},
pages = {891--900},
doi = {10.1111/dom.15382}
}
EUVIMED